Genetic variation may increase risk of liver damage in patients with chronic hepatitis B

Genetic variation may increase risk of liver damage in patients with chronic hepatitis B
First author Dr. Rasha El Sharkawy. Credit: The Westmead Institute for Medical Research

A new study has shown that genetic variation may increase the risk of severe liver damage in Caucasians with chronic hepatitis B infection.

Researchers from the Westmead Institute for Medical Research found that Caucasian patients with a variation in their STAT4 gene were more likely to experience inflammation and severe liver fibrosis.

Dr. Rasha El Sharkawy, the first author of the study, said the findings add to the growing body of evidence that demonstrates a link between genes and the progression of hepatitis B.

"The progression of liver injury in hepatitis B can vary significantly among patients, which indicates that genetic factors may play a role," Dr. El Sharkawy said.

The STAT4 gene is part of the body's immune response against viruses and regulates tissue inflammation, fibrosis and anti-viral activity.

"We found that patients with the risk had lower expression of STAT4 in their liver and immune cells, reducing their immune response against hepatitis B and their production of interferon gamma, a protein responsible for moderating fibrosis.

"This may, at least partially explain why patients with the variation experience poorer liver health," Dr. El Sharkawy explained.

Approximately one third of the world's population have come into contact with hepatitis B, with 350-400 million people developing a chronic infection. If left untreated, can lead to liver injury, liver cancer, and liver failure, with more than one million deaths attributed to cirrhosis and cancer each year.

"Not everyone who comes into contact with the virus will develop a chronic infection, but those that do, require treatment to prevent severe complications, including and damage," Dr. El Sharkawy said.

Professor Jacob George and Associate Professor Mohammed Eslam, leaders of the research study, said that with further study, researchers could better understand how the STAT4 gene affects the progression of B, so that they can prevent and failure in at-risk groups.


Explore further

Can aspirin stop liver cancer in hepatitis B patients?

More information: R. El Sharkawy et al, A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B, Alimentary Pharmacology & Therapeutics (2018). DOI: 10.1111/apt.14866
Provided by Westmead Institute for Medical Research
Citation: Genetic variation may increase risk of liver damage in patients with chronic hepatitis B (2018, July 27) retrieved 16 February 2019 from https://medicalxpress.com/news/2018-07-genetic-variation-liver-patients-chronic.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more